Atacand, 32mg pills, 28pcs

Composition

1 tablet contains candesartan cilexetil 32 mg

Pharmacological action

Atacand has a hypotensive effect.

Selectively blocks angiotensin II (AT-1 type) receptors.

Indications

Arterial hypertension.

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy.

Experimental studies have shown that the use of candesartan leads to impaired renal function in the fetus in the late stages of development, as well as in the neonatal period. The mechanism of this action is probably related to the effect of the drug on the renin-angiotensin-aldosterone system.

In humans, fetal renal perfusion, which depends on the state of the renin-angiotensin-aldosterone system, begins in the second trimester of pregnancy. Thus, the risk to the fetus increases when taking the drug in the second trimester.

It has not been established whether candesartan is excreted in breast milk.

If it is necessary to use the drug during lactation, breastfeeding should be discontinued due to the potential for negative side effects in the child.

In experimental studies, candesartan was found in the milk of lactating rats.

Contraindications

Hypersensitivity; pregnancy, breast-feeding; childhood.

Side effects

From the central nervous system:  often ( more than 2%) – headache, dizziness.

From the side of laboratory parameters:  increased AST activity (slightly higher than in the placebo groups). In general, there were no clinically significant changes in laboratory parameters when taking Atacand.

Other services:  often ( more than 2%) – back pain.

Clinical trials showed good tolerability of the drug, the frequency of side effects was comparable to placebo, did not depend on the dose of the drug, as well as on the age and gender of the patient. In general, side effects were moderate and temporary. The number of cases of discontinuation of the drug due to side effects was similar to the number in the group of patients taking candesartan cilexetil and placebo.

A causal relationship between Atakand and the described side effects has not been established.

How to take, course of use and dosage

Atacand is recommended to be prescribed at a dose of 8 mg 1 time/day. The maximum therapeutic effect is achieved 4 weeks after the start of therapy. In the absence of the necessary clinical effect, the dose can be increased to 16 mg / day.

Tablets are taken 1 time / day regardless of food intake.

When prescribing the drug to the elderly, patients with mild or moderate renal impairment (creatinine clearance>30 ml/min/1.73 m2) or with chronic liver disease of mild or moderate severity, no dosage adjustment is required. When prescribing the drug to patients with severe renal impairment (creatinine clearance 2) the initial dose should be 4 mg.

There are no clinical data on the use of the drug in patients with severe liver diseases (cirrhosis). In this regard, such patients are recommended to start treatment with a daily dose of 4 mg.

The drug can be used both as monotherapy and in combination with other antihypertensive drugs (thiazide diuretics, calcium channel blockers).

Overdose

Analysis of the pharmacological properties of the drug suggests that the main manifestation of overdose may be a clinically pronounced decrease in blood pressure and dizziness. Individual cases of overdose of the drug (up to 672 mg of candesartan cilexetil) were described, which resulted in recovery of patients without serious consequences.

Treatment

With the development of clinically pronounced arterial hypotension, it is necessary to conduct symptomatic treatment and monitor the patient’s condition. Lay the patient down, lift the head end of the bed. If necessary, the volume of circulating plasma should be increased, for example, by intravenous use of an isotonic sodium chloride solution. If necessary, sympathomimetic drugs may be prescribed. Elimination of candesartan by hemodialysis is unlikely.

Special instructions

When prescribing Atacand to patients with renal artery stenosis (bilateral or single artery stenosis), it should be taken into account that drugs that affect the renin-angiotensin-aldosterone system (ACE inhibitors) may increase the concentration of urea and creatinine in the blood serum. There is a possibility (unconfirmed) that similar effects may be observed with the use of angiotensin II antagonists.

Patients treated with 12.5 mg hydrochlorothiazide are well tolerated by the subsequent use of Atacand at a dose of 8 mg. Patients also tolerate concomitant therapy with hydrochlorothiazide up to 25 mg and Atacand 8-16 mg for 8 weeks. However, with a marked decrease in BCC (when using diuretics in high doses), symptomatic hypotension may occur, which is typical for other drugs that affect the renin-angiotensin-aldosterone system. Obviously, this condition needs to be corrected before using the Atakand.

Concomitant use of Atacand with potassium-sparing diuretics that do not remove potassium from the body can theoretically lead to an increase in serum potassium concentrations. Caution should be exercised when using this combination.

Use in pediatrics

The clinical efficacy and safety of Atacand in children has not been established.

Form of production

Pills.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

3 years

Active ingredient

Candesartan

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Hypertension, Heart Failure